TW202227143A - 放射性藥物及方法 - Google Patents

放射性藥物及方法 Download PDF

Info

Publication number
TW202227143A
TW202227143A TW110131903A TW110131903A TW202227143A TW 202227143 A TW202227143 A TW 202227143A TW 110131903 A TW110131903 A TW 110131903A TW 110131903 A TW110131903 A TW 110131903A TW 202227143 A TW202227143 A TW 202227143A
Authority
TW
Taiwan
Prior art keywords
acid
dotatate
amount
compounds
octreonic
Prior art date
Application number
TW110131903A
Other languages
English (en)
Chinese (zh)
Inventor
喬 麥肯
賈斯蒂娜 凱莉
保羅 比隆
Original Assignee
加拿大商探針開發暨商業化中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大商探針開發暨商業化中心 filed Critical 加拿大商探針開發暨商業化中心
Publication of TW202227143A publication Critical patent/TW202227143A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW110131903A 2020-08-27 2021-08-27 放射性藥物及方法 TW202227143A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063071138P 2020-08-27 2020-08-27
US63/071,138 2020-08-27

Publications (1)

Publication Number Publication Date
TW202227143A true TW202227143A (zh) 2022-07-16

Family

ID=80352743

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110131903A TW202227143A (zh) 2020-08-27 2021-08-27 放射性藥物及方法

Country Status (9)

Country Link
US (2) US11439714B2 (enExample)
EP (1) EP4204011A4 (enExample)
JP (1) JP2023540240A (enExample)
KR (1) KR20240121161A (enExample)
CN (1) CN116528904A (enExample)
AU (1) AU2021330382A1 (enExample)
CA (1) CA3190855A1 (enExample)
TW (1) TW202227143A (enExample)
WO (1) WO2022043754A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204872A2 (en) * 2017-05-05 2018-11-08 Fusion Pharmaceuticals Inc. Igf-1r monoclonal antibodies and uses thereof
JP2023539990A (ja) 2020-07-13 2023-09-21 ポイント バイオファーマ インコーポレイテッド 放射性薬剤および方法
WO2023164769A1 (en) * 2022-03-02 2023-09-07 Point Biopharma, Inc. Radiopharmaceutical and methods
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2025171492A1 (en) 2024-02-14 2025-08-21 Alpha-9 Oncology Inc. Stable radiopharmaceutical compositions and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1096278A (en) 1913-08-25 1914-05-12 American Radiator Co Service-outlet fitting for pneumatic cleaning systems.
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6358245B1 (en) 1998-02-19 2002-03-19 Curon Medical, Inc. Graphical user interface for association with an electrode structure deployed in contact with a tissue region
EP1596705B1 (en) 2003-02-05 2018-09-12 Arthrocare Corporation Temperature indicating electrosurgical apparatus
CN100418585C (zh) 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
CN115089242A (zh) 2016-05-23 2022-09-23 Ip2Ipo创新有限公司 末端执行器和持针器
US10537399B2 (en) 2016-08-16 2020-01-21 Ethicon Llc Surgical tool positioning based on sensed parameters
US10537394B2 (en) 2016-12-19 2020-01-21 Ethicon Llc Hot device indication of video display
US20200030466A1 (en) * 2018-07-25 2020-01-30 Advanced Accelerator Applications (Italy) Srl Stable, concentrated radionuclide complex solutions
US10596276B2 (en) * 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
WO2020064693A1 (en) * 2018-09-25 2020-04-02 Advanced Accelerator Applications (Italy) Srl Combination therapy
CN112969675B (zh) * 2018-10-31 2024-12-20 意大利国际先进加速器应用有限公司 用于合成放射性核素络合物的方法

Also Published As

Publication number Publication date
US20220387637A1 (en) 2022-12-08
WO2022043754A2 (en) 2022-03-03
US20220062447A1 (en) 2022-03-03
EP4204011A4 (en) 2025-06-18
WO2022043754A3 (en) 2022-04-07
CN116528904A (zh) 2023-08-01
CA3190855A1 (en) 2022-03-03
US11439714B2 (en) 2022-09-13
AU2021330382A9 (en) 2024-02-08
JP2023540240A (ja) 2023-09-22
EP4204011A2 (en) 2023-07-05
AU2021330382A1 (en) 2023-05-04
KR20240121161A (ko) 2024-08-08

Similar Documents

Publication Publication Date Title
US12558440B2 (en) Radiopharmaceutical and methods
US11129912B1 (en) Radiopharmaceutical and methods
US11439714B2 (en) Radiopharmaceutical and methods
CN1033143C (zh) 放射性药物制剂的制备方法
JP7358451B2 (ja) 安定な濃厚放射性核種錯体溶液
US20220401593A1 (en) Stable, concentrated radiopharmaceutical composition
JP2004517854A (ja) 安定化放射性医薬組成物
CN101257929B (zh) 包含龙胆酸的稳定的123-i放射性药物
CN116547007A (zh) 放射性药物和方法
JP2025505307A (ja) 放射性医薬品及び方法
CN118742332A (zh) 放射性药物和方法
HK40088578A (en) Radiopharmaceutical and methods
CN114569545A (zh) 一种稳定的米托蒽醌制剂
RU2859685C2 (ru) Фармацевтическая композиция в форме раствора для внутривенного введения на основе металлокомплексов бета-эмиттеров: лютеций-177 или тербий-161 и агонистов соматостатиновых рецепторов: DOTA-TATE, DOTA-TOC, DOTA-NOC
CN114569544A (zh) 一种米托蒽醌注射剂的制备方法
EP4422701A1 (en) Combination therapy of radionuclide complex